Search results
DoorDash projects quarterly core profit below estimates on higher costs
MSN News· 4 days agoBy Granth Vanaik and Waylon Cunningham (Reuters) - DoorDash projected second-quarter core profit...
Novo Nordisk Stock Falls After Pricing Pressure Mounts for Wegovy
The Wall Street Journal· 4 days agoNovo Nordisk’s American depositary receipts slipped nearly 3%, despite reporting higher quarterly...
DoorDash disappoints Wall Street with downbeat quarterly core profit
Reuters via Yahoo Finance· 4 days agoShares of DoorDash sank more than 14% in extended trading on Wednesday after it projected...
India's Tata Chemicals posts first loss in 9 years on one-time charge, poor soda ash demand
Reuters· 7 days ago, opens new tab reported its first quarterly loss in nine years on Monday, hurt by a one-time charge incurred in its UK operations along with lower prices ...
Macerich Posts $127M Quarterly Loss, May Exit Properties
The Real Deal· 4 days agoDuring the quarter, Macerich’s funds from operations fell to $74.6 million, from $95.9 million a...
Is Eli Lilly Stock A Buy After Weight-Loss Drug Crushes Quarterly Sales Forecasts?
Investor's Business Daily· 6 days agoIn 2023, Eli Lilly earned $6.32 a share, minus some items, on $34.12 billion in sales. Profit fell...
DoorDash projects quarterly core profit below estimates on higher costs
MSN News· 4 days ago(Corrects paragraph 7 to say absorption of costs is going to wane, not weigh) By Granth Vanaik and...
Incyte misses quarterly profit on weak sales of lead drug
Reuters via Yahoo Finance· 6 days agoIncyte Corp on Tuesday reported first-quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi, sending its shares down 2.4%. The company is ...
Dow Jones Rallies As Much As 350 Points After Wild Wednesday; Apple Up Ahead Of Earnings, Carvana...
Investor's Business Daily· 3 days agoFor long-term holders in Meta who hold an outstanding profit in the stock, they could consider...
Incyte misses quarterly profit on weak sales of lead drug
Reuters· 6 days ago, opens new tab on Tuesday reported first-quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi, sending its shares down 2.4%. The company ...